MCID: MLG012
MIFTS: 21

Malignant Epithelial Mesothelioma

Categories: Cancer diseases

Aliases & Classifications for Malignant Epithelial Mesothelioma

MalaCards integrated aliases for Malignant Epithelial Mesothelioma:

Name: Malignant Epithelial Mesothelioma 12 15
Epithelioid Mesothelioma, Malignant 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4489
NCIt 50 C7985
SNOMED-CT 68 65278006
UMLS 73 C0862312

Summaries for Malignant Epithelial Mesothelioma

MalaCards based summary : Malignant Epithelial Mesothelioma, also known as epithelioid mesothelioma, malignant, is related to peritoneal serous papillary adenocarcinoma and benign mesothelioma. An important gene associated with Malignant Epithelial Mesothelioma is PTGER4 (Prostaglandin E Receptor 4). The drugs Vinorelbine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include testis, and related phenotypes are homeostasis/metabolism and liver/biliary system

Related Diseases for Malignant Epithelial Mesothelioma

Graphical network of the top 20 diseases related to Malignant Epithelial Mesothelioma:



Diseases related to Malignant Epithelial Mesothelioma

Symptoms & Phenotypes for Malignant Epithelial Mesothelioma

MGI Mouse Phenotypes related to Malignant Epithelial Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.35 DAB2 PHYH PTGER4 THBD WT1
2 liver/biliary system MP:0005370 8.92 PHYH PTGER4 THBD WT1

Drugs & Therapeutics for Malignant Epithelial Mesothelioma

Drugs for Malignant Epithelial Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
4 Antimitotic Agents Phase 3,Phase 2,Phase 1
5 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
6 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
7 Mitomycins Phase 3
8 Antibiotics, Antitubercular Phase 3
9 Anti-Bacterial Agents Phase 3
10 Alkylating Agents Phase 3
11
Vinblastine Approved Phase 2 865-21-4 241903 13342
12
leucovorin Approved Phase 2,Phase 1 58-05-9 6006 143
13
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
14
Gemcitabine Approved Phase 2 95058-81-4 60750
15
Belinostat Approved, Investigational Phase 2 866323-14-0
16
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
17
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
18
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
19
Trioxsalen Approved Phase 2 3902-71-4 5585
20
Bevacizumab Approved, Investigational Phase 2 216974-75-3
21
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
22
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
23
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
24
Pembrolizumab Approved Phase 2 1374853-91-4
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
26
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
27
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
28
Cediranib Investigational Phase 2,Phase 1 288383-20-0 9933475
29
Maleic acid Experimental Phase 2,Phase 1 110-16-7 444266
30
Vatalanib Investigational Phase 2 212141-54-3 151194
31 Antirheumatic Agents Phase 2
32 Immunologic Factors Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 2
34 Vitamin B Complex Phase 2,Phase 1
35 Folic Acid Antagonists Phase 2,Phase 1
36 Folate Phase 2,Phase 1
37 Immunosuppressive Agents Phase 2
38 Dermatologic Agents Phase 2
39 Vitamin B9 Phase 2,Phase 1
40 Antimetabolites Phase 2
41 Antiviral Agents Phase 2
42 Anti-Infective Agents Phase 2
43 Histone Deacetylase Inhibitors Phase 2
44 Angiogenesis Inhibitors Phase 2
45 Protein Kinase Inhibitors Phase 2,Phase 1
46 tyrosine Phase 2
47
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
48 Semaxinib Phase 2
49 Angiogenesis Modulating Agents Phase 2
50 Photosensitizing Agents Phase 2

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
2 Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma Completed NCT00821860 Phase 3
3 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
4 S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery Completed NCT00003723 Phase 2 gemcitabine hydrochloride
5 PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Completed NCT00365053 Phase 2 belinostat
6 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Completed NCT00243074 Phase 2 cediranib maleate
7 Gefitinib in Treating Patients With Malignant Mesothelioma Completed NCT00025207 Phase 2 gefitinib
8 Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung Completed NCT00039182 Phase 2 erlotinib hydrochloride
9 Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00227630 Phase 2 cisplatin;pemetrexed disodium
10 Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma Completed NCT00509041 Phase 2 dasatinib
11 PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma Completed NCT00053885 Phase 2 PTK787/ZK 222584
12 Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery Completed NCT00309946 Phase 2 cediranib maleate
13 SU5416 in Treating Patients With Malignant Mesothelioma Completed NCT00006014 Phase 2 semaxanib
14 Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma Completed NCT00054002 Phase 2 porfimer sodium
15 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma Completed NCT00027703 Phase 2 gemcitabine hydrochloride;cisplatin
16 Capecitabine in Treating Patients With Malignant Mesothelioma Completed NCT00004183 Phase 2 capecitabine
17 Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. Completed NCT00107432 Phase 2 sorafenib tosylate
18 Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00334594 Phase 2 Cisplatin;Pemetrexed
19 Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Active, not recruiting NCT01064648 Phase 1, Phase 2 Cediranib Maleate;Cisplatin;Pemetrexed Disodium
20 Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting NCT02399371 Phase 2
21 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy Active, not recruiting NCT01085630 Phase 2 pemetrexed disodium
22 Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma Terminated NCT01861301 Phase 2 Tivantinib
23 AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma Withdrawn NCT01105390 Phase 2 cisplatin;pemetrexed disodium
24 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
25 First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin Recruiting NCT03507452 Phase 1 BAY2287411;BAY2287411
26 Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma Recruiting NCT03228537 Phase 1 Atezolizumab;Cisplatin;Pemetrexed Disodium
27 Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Active, not recruiting NCT02639091 Phase 1 BAY 94-9343;Pemetrexed;Cisplatin
28 Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment Terminated NCT00585845 Phase 1
29 Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma Recruiting NCT02672033 Not Applicable
30 Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107 Terminated NCT00898547
31 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Terminated NCT00904514

Search NIH Clinical Center for Malignant Epithelial Mesothelioma

Genetic Tests for Malignant Epithelial Mesothelioma

Anatomical Context for Malignant Epithelial Mesothelioma

MalaCards organs/tissues related to Malignant Epithelial Mesothelioma:

41
Testis

Publications for Malignant Epithelial Mesothelioma

Articles related to Malignant Epithelial Mesothelioma:

# Title Authors Year
1
Establishment of a human malignant fibrous mesothelioma cell line and the biological characteristics compared with malignant epithelial mesothelioma cell line. ( 18667024 )
2008
2
Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage. ( 16679752 )
2006
3
Immunophenotypings of malignant epithelial mesothelioma and their roles in the differential diagnosis. ( 15315156 )
2004
4
Malignant epithelial mesothelioma of the peritoneum: observations on a problem case. ( 8837340 )
1996
5
Malignant epithelial mesothelioma presenting as cardiac tamponade. ( 8299643 )
1993
6
Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant epithelial mesothelioma. ( 3414598 )
1988
7
Malignant epithelial mesothelioma of the anterior mediastinum. ( 6585691 )
1984

Variations for Malignant Epithelial Mesothelioma

Expression for Malignant Epithelial Mesothelioma

Search GEO for disease gene expression data for Malignant Epithelial Mesothelioma.

Pathways for Malignant Epithelial Mesothelioma

GO Terms for Malignant Epithelial Mesothelioma

Biological processes related to Malignant Epithelial Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 8.62 PTGER4 THBD

Sources for Malignant Epithelial Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....